Marodyne LiV Device
Low Intensity Vibration
Fighting Bone Diseases
Marodyne LiV applies science to bring back the balance between the rates of growing bone mineral density by activating osteoblast activity (bone builders) and inhibiting osteoclast activity (bone resorbing).
Increasing bone mineral density
Regular use of Low-intensity vibration with Marodyne LiV stimulates the production cells in the same natural way as day-to-day movements like walking, running, and lifting objects, with just 10 minutes’ sessions a day.
Improve balance & coordination
Regular exercise, such as walking and running may not be possible for frail, disabled, elderly, or infirm populations. Low-intensity vibration (LiV), with accelerations against the gravity of less than 1g, is a safe and effective approach to this problem.
Vibration treatment for astronauts
If not treated, osteoporosis affected women can lose about 1.5% of their bone mass in the lumbar spinal region, in the hips or femoral neck within one year. An astronaut, by comparison, can lose this same amount in a single month.
To mitigate astronaut’s bone loss while in space, NASA (National Aeronautics and Space Administration), put together a team, led by professor Clinton Rubin, to research and develop the low-intensity vibration concept, which took considerable amounts of research over many years.
The result was the creation of a vibration platform that you stand on as it transmits stimuli to the bones. These specific, low-intensity stimuli activate the body’s cells and contribute to maintaining and building up bones and muscles.
Vitality for muscles and bones
Marodyne LiV (low-intensity vibration) offers a safe way to fight against muscle weakness and nerve disorders, contributing to muscle mass increase and improving mobility.
Stimulate blood circulation
Increasing circulation by using Marodyne LiV means that lymph and blood return can be vastly improved, with vibrations at a very low intensity of 15 Hz, just 10 minutes a day.
Research & science supports Marodyne LiV
The Marodyne LiV product draws on a solid, medical foundation. Known globally as the only provider of a fully medically certified (under the EU Medical Devices Directive), safe Low-intensity Vibration (LiV) platform, Marodyne is supervised by a scientific advisory board with leading experts from the fields of biomedicine, orthopedics, osteoporosis, metabolism, rehabilitation medicine, and stem cell research. The starting points for the development of the treatment were orthopedics, osteoporosis, and space medicine: the future of the research is increasingly determined by new studies and findings from the field of stem cell biology.
Professor Rubin serves as the Chief Scientific Officer at Marodyne LiV. He is also SUNY Distinguished Professor and Chair of the Department of Biomedical Engineering at the State University of New York at Stony Brook, and Director of the NYSTAR Center for Advanced Technology in Medical Biotechnology.
Q&A Marodyne LiV Device
with Sara Meeks
Know who is behind the scenes of Marodyne LiV
Clinton Rubin, Ph.D, is SUNY Distinguished Professor and Chief Scientific Officer of BTT-Health GmbH, who has spent his scientific career trying to understand how mechanical signals influence the body. One of his key findings has been that extremely low magnitude mechanical signals, delivered in the form of Low-intensity Vibration (LiV), can dictate the regeneration patterns of mesenchymal stem cells (MSCs) found within the body to stimulate musculoskeletal tissues and suppress the formation of fat¹.
Professor Clinton Rubin, Ph.D.
His team has discovered, that Low-intensity Vibration promotes the building of lean muscle mass and the conditioning of muscle reflexes. It is the goal of all biomedical scientists to see the work that we do in the laboratory translate to the clinic, to help the health and well-being of patients.
¹ Luu YK, Capilla E, Rosen C, Gilsanz V, Pessin JE, Judex, Rubin CT, (2009) Mechanical stimulation of mesenchymal stem cell proliferation and differentiation promotes osteogenesis while preventing dietary-induced obesity. J.Bone Miner.Res. 24, 50-61